NeoCG (ECG technology from WSU)
NeoCG is an improved screening/diagnostic tool for cardiovascular illnesses. Currently the ECG is the sole primary screening/diagnostic tool. The NeoCG delivers an increase in the precision of diagnosis enabling a reductions in the number of hospitalisations and a reduction in fatalities due to limited cardiac diagnoses. The current Electrocardiography market is worth more that US$1.5Bn p.a., with maintenance contracts of around the same value. Two major Australian hospitals have invited clinical trials of NeoCG.